Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
about
Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-gamma and TNF-alpha.Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.Gene Therapies for Cancer: Strategies, Challenges and Successes.mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanomaOxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.MDA-7/IL-24: multifunctional cancer killing cytokineUrsolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expressionMolecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities.A conditionally replicating adenovirus expressing IL-24 acts synergistically with temozolomide to enhance apoptosis in melanoma cells in vitro.JLK1486, a N,N-[(8-hydroxyquinoline)methyl]-substituted benzylamine analogue, inhibits melanoma proliferation and induces autophagy.Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo.Glioma-amplified sequence KUB3 influences double-strand break repair after ionizing radiation.Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies.Trps1 is associated with the multidrug resistance of lung cancer cell by regulating MGMT gene expression.Paracrine effects of mesenchymal stem cells induce senescence and differentiation of glioblastoma stem-like cells.
P2860
Q33533655-9D6AF736-CB6B-474D-A7A5-0469B462A53EQ33738887-6C54654E-0F73-44D3-9816-369868EE121EQ35186312-FDDE9F1E-07CB-4C08-9264-F03316EE41AFQ35189796-574786BA-44AE-4F14-B08A-334280442B1CQ35234354-CAE1FEE8-5E3B-48C0-AF8D-06583EC0E2E2Q35234429-E969BE72-4802-4564-9FB2-28A8C969E0FCQ36248193-C8B44124-F8C7-462E-82AD-16DC9DA8BD01Q37144157-2218260A-0549-4B5C-ADF1-6D9CBF040AB8Q38174692-96210FA5-7117-47DB-A3BE-54B10F64C095Q38733784-39FAD6E4-8C29-48CB-B42E-E91B78E23A4FQ38964432-20B22FE7-15CE-43ED-890D-527A4B9B23ACQ39162230-C3B4272F-A32F-4256-B785-91BD1F21EBB7Q41823773-A3D43B21-F779-4E1F-8C74-57C88E46A60BQ42201282-91B44BAA-C897-4E77-ADF5-C3ECCD15E458Q45197517-3638AEE3-12DD-49C4-AEE8-8EA11FE0B6B6Q49679681-C76E9BF0-C19F-4471-B78F-6E5C8754A427Q51415292-32412D03-CEB6-4129-96F9-BB2226A94134Q52956451-069D92F4-B69A-4CAD-BC29-F187F7360A75
P2860
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Interleukin-24 overcomes temoz ...... erase in human melanoma cells.
@en
Interleukin-24 overcomes temoz ...... erase in human melanoma cells.
@nl
type
label
Interleukin-24 overcomes temoz ...... erase in human melanoma cells.
@en
Interleukin-24 overcomes temoz ...... erase in human melanoma cells.
@nl
prefLabel
Interleukin-24 overcomes temoz ...... erase in human melanoma cells.
@en
Interleukin-24 overcomes temoz ...... erase in human melanoma cells.
@nl
P2093
P2860
P1476
Interleukin-24 overcomes temoz ...... erase in human melanoma cells.
@en
P2093
Dora Bocangel
Elizabeth A Grimm
Mingzhong Zheng
Nancy Poindexter
Rajagopal Ramesh
Suhendan Ekmekcioglu
Sunil Chada
P2860
P304
P356
10.1158/1535-7163.MCT-08-0516
P577
2008-12-03T00:00:00Z